Patients who require paralysis with cisatracurium as part of their clinical care in ICU

Critical Illness

Respiratory Distress Syndrome, Adult

Neuromuscular Blockade

Respiratory Failure

Paralysis

ARDS, Human

A single dose of 0.2 mg/kg intravenous bolus cisatracurium will be administered and blood samples will be taken before and at least 7 occasions post dose (at 1, 5, 10, 12, 15, 20, 30, and/or 60 minutes after a single bolus).

cisatracurium

Faculty of Medicine Ramathibodi Hospital

The Study of Pharmacokinetics and Pharmacodynamics of Cisatracurium

The Study of Pharmacokinetics and Pharmacodynamics of a Loading Dose Cisatracurium in Critically Ill Patients

Data will be collected in case-record form and managed by Microsoft Office Excel. Statistical analyses will be performed using SPSS.

Analysis of time to maximum concentration will be performed with a nonlinear mixed-effects population modelling approach as implemented in NONMEM software.

Analysis of half-life will be performed with a nonlinear mixed-effects population modelling approach as implemented in NONMEM software.

Analysis of clearance will be performed with a nonlinear mixed-effects population modelling approach as implemented in NONMEM software.

Analysis of elimination rate constant will be performed with a nonlinear mixed-effects population modelling approach as implemented in NONMEM software.

laudanosine/palavik

The Study of Pharmacokinetics and Pharmacodynamics of Cisatracurium

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus